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SHORT COMMUNICATION
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S UMM A R Y
We assessed the impact on measured burden and
outcomes of the revised World Health Organization
and Malawi guidelines reclassifying people with single
(including ‘scanty’) positive smears as smear-positive
pulmonary tuberculosis cases. In a retrospective cohort
in rural Malawi, 567 (34%) of 1670 smear-positive
episodes were based on single positive smears (including
176 with scanty smears). Mortality rates and the
proportion starting treatment were similar in those with
two positive smears or single, non-scanty smears. Those
with single scanty smears had higher mortality and a
lower proportion starting treatment. The reclassification
will increase the reported burden substantially, but
should improve treatment access.
K E Y WORD S : tuberculosis; microscopy; HIV
IN 2007, the World Health Organization (WHO)
issued new guidelines for human immunodeficiency
virus (HIV) prevalent settings to increase the sensi-
tivity and reduce the delays in the diagnosis of
tuberculosis (TB) among HIV-positive patients.1 One
positive sputum smear would become sufficient to
classify a patient as a smear-positive case if the patient
was known or suspected to be HIV-infected.
In 2009, the WHO recommended lowering the
threshold for defining smear-positivity to one acid-
fast bacillus (AFB) per smear in settings with well-
functioning external quality assessment schemes, thus
including smears previously denoted as scanty (,10
AFB/100 high power fields).2
In 2012, the National Tuberculosis Programme
(NTP) in Malawi adopted these approaches, consid-
ering patients with71 smear-positive sputum sample
(including single scanty smears) to be smear-positive
cases. To minimise workload, two sputum specimens
are now collected instead of three. Opt-out HIV
testing for individuals with possible TB was also
introduced.3
The likely impact of these policy changes on
measured TB rates and the outcome in those with
single positive smears are unknown. We analysed the
frequency of single positive smears and the outcomes
of these patients in the 15 years before the guideline
changes in Karonga District, Malawi, where smear-
positive TB incidence is currently ~80 per 100 000
adults per year and HIV prevalence ~8%.4,5
METHODS
A retrospective cohort study was conducted of
patients investigated for pulmonary TB from 1998
to 2012 within the Karonga Prevention Study,
northern Malawi: details are given elsewhere.4
Project staff collect sputum from individuals with
chronic cough at the hospital and peripheral clinics.
In line with NTP guidelines, smears are processed in
the project laboratory using fluorescence microsco-
py and Ziehl-Neelsen confirmation of positives. The
laboratory participates in a well functioning exter-
nal quality control system provided by the UK
National External Quality Assessment Service.
Consenting patients are counselled and tested for
HIV. Patients are followed annually after completing
treatment.
For research purposes, we attempted to obtain at
least three sputum samples per patient at diagnosis. In
the present study, we analysed data based on the first
two smears taken during a 7-day period, defined as a
screening episode. We differentiated single scanty and
single non-scanty smears. We present the frequency of
these patients and the outcomes, stratified by HIV
status.
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RESULTS
Between January 1998 and December 2012, 35 560
smears from 11785 screening episodes (in 9179
individuals) were examined: 1150 submitted a single
sample, 570 submitted two and 10065 submitted
73. Of these, 2426 (21%) went on to start anti-
tuberculosis treatment.
Overall, including the first three smears, 1386
(12%) episodes were smear-positive, of which 331
(24%) were positive on only a single smear. Including
only the first two smears gives 1335 (11%) smear-
positive episodes, of which 567 (42%) were positive
on only a single smear, including 176 with only a
scanty smear. If the first two smears had been
examined using fluorescence microscopy alone, the
results would have been similar, with 1441 (12%)
smear-positive episodes, of which 527 (37%) were
positive on only a single smear and 168 were scanty
smears.
Patient characteristics in the three groups (single
non-scanty smear, single scanty smear, .1 positive)
are compared in Table 1. The age and proportion that
had had previous TB were similar in all groups. There
was a higher proportion of women among those with
single positive smears, which might be explained by
the higher proportion of unknown status and HIV-
positives in this group (69% vs. 56% among those
with .1 positive smear) (P , 0.001 for both
comparisons).
Overall, 91 (16%) of the 567 with a single positive
smear died within 1 year, compared to 101/768
(13%) with .1 positive (P¼ 0.1, Table 2). Mortality
was higher among those with only a single scanty
smear (35/176, 20%) than those with a single non-
scanty smear (56/391, 14%, P ¼ 0.1). Mortality
among patients with a single positive smear was
higher among patients with unknown (41/102, 40%)
and positive status (45/289, 16%) than among HIV-
negative patients (5/176, 3%).
The proportion starting treatment within 1 year
was similar in those with a single non-scanty smear
(89%) and those with .1 positive smear (90%), but
lower in those with a single scanty smear (79%, P ,
0.001). The proportions were similar among HIV-
positives (274/289, 95%) and negatives (166/176,
94%), but lower in those with unknown HIV status
(47/102, 46%). Only 2% of those with a single scanty
smear were started on anti-tuberculosis treatment due
to a later positive smear or a positive culture result;
the remainder were started on clinical grounds. Of
348 patients with single non-scanty smears, 217
(62%) were culture-positive for Mycobacterium
tuberculosis compared to 43% (59/139) of those
with single scanty smears and 63% (434/691) of
those with .1 positive smear.
Among patients with single positive smears not
starting anti-tuberculosis treatment, 43% (34/80) had
cultures later found to be positive; most (69%) were
not HIV-tested. Of patients not started on anti-
tuberculosis treatment, 35% (28/80) died (after a
median of 6 days, interquartile range 3–13), including
17 who were culture-positive.
DISCUSSION
In this study, single non-scanty and single scanty
smear screening episodes were common, especially if
only two sputum samples were examined. Similar
results were found in Bangladesh.6 Reclassifying
patients with scanty and single positive smears will
considerably increase the number of smear-positive
patients.
Similar proportions of patients with single positive
smears and .1 positive smear were started on anti-
tuberculosis treatment, concurring with other studies
in which about 85% of patients with a positive smear
were started on anti-tuberculosis treatment.7 How-
ever, patients with single scanty smears were less
Table 1 Study population and baseline characteristics of presumptive tuberculosis patients, considering results that would have
been seen if only the first two smears were examined
Episodes
Total number of screening episodes (n ¼ 11785)
Single positive smear
(n ¼ 567, 4.8%)
n (%)
Single non-scanty smear
(n ¼ 391, 3.3%)
n (%)
Single scanty smear
(n ¼ 176, 1.5%)
n (%)
.1 positive smear
(n ¼ 768, 6.5%)
n (%)
Sex
Male 258 (45.5) 180 (46.0) 78 (44.3) 432 (56.3)
Female 309 (54.5) 211 (54.0) 98 (55.7) 336 (43.7)
Age, years, median [IQR] 35.3 [28.3-46.3] 34.9 [27.8-44.7] 37.5 [28.9-49.7] 35.8 [28.5-45.4]
History of previous anti-tuberculosis treatment
Yes 53 (9.3) 39 (10.0) 14 (7.9) 73 (9.5)
No 514 (90.7) 352 (90.0) 162 (92.1) 695 (90.5)
HIV status
Positive 289 (51.0) 200 (51.2) 89 (50.6) 305 (39.7)
Negative 176 (31.0) 133 (34.0) 43 (24.4) 340 (44.3)
Unknown 102 (18.0) 58 (14.8) 44 (25.0) 123 (16.0)
IQR¼ interquartile range; HIV¼ human immunodeficiency virus.
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likely to start treatment and experienced higher
mortality. The high mortality and lower proportions
starting treatment among those with unknown HIV
status probably reflects early death or loss to follow-
up before HIV testing could be performed. Given the
high HIV prevalence among TB patients (56% in
2006) in this setting,8 most of those with unknown
status were probably HIV-positive. Rapid point-of-
care tests such as the Xpertw MTB/RIF assay
(Cepheid, Sunnyvale, CA, USA) may reduce these
early losses.9
Under current WHO and Malawi guidelines, all
567 presumptive TB patients would have been HIV-
tested unless they opted out, resulting in 22% more
presumptive TB patients knowing their HIV status.
Based on the updated criteria for smear-positive TB,
all 567 patients (þ16%) would probably have been
started on anti-tuberculosis treatment earlier. All
HIV-positive TB patients are eligible for antiretroviral
therapy treatment,10 which should further reduce
mortality.11
These changes increase the sensitivity of TB
diagnosis, and are likely to reduce treatment delay
and mortality among a group of patients who
previously had a poor prognosis. The effect on TB
notification rates will be substantial; it will be
important to note this classification shift when
analysing trends over time.
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R E S UM E
Nous avons estime´ l’impact des directives re´vise´es de
l’Organisation Mondiale de la Sante´ et du Malawi sur la
mesure du fardeau de la tuberculose (TB) et des re´sultats
du traitement. Celles-ci reclassent les patients avec un
seul frottis positif, meˆme « faible », comme cas de TB
pulmonaire a` frottis positif. Dans une e´tude de cohorte
re´trospective en zone rurale du Malawi, sur 1670
e´pisodes a` frottis positifs, 567 (34%) e´taient base´s sur
un seul frottis positif (dont 176 avec un frottis pauvre).
Les taux de mortalite´ et la proportion de ceux qui ont
de´marre´ un traitement e´taient similaires chez les patients
avec deux frottis positifs ou un seul frottis abondant.
Ceux qui avaient un frottis unique et pauvre avaient une
mortalite´ plus e´leve´e et une moindre proportion de mise
en œuvre du traitement. Cette reclassification va
sensiblement accroitre le fardeau, mais elle devrait
ame´liorer l’acce`s au traitement.
R E S UM E N
En el presente estudio se evaluo´ la repercusio´n sobre la
carga de morbilidad por tuberculosis (TB) y los
desenlaces clı´nicos de las normas revisadas de la
Organizacio´n Mundial de la Salud y de Malawi, que
reclasifican a las personas que presentan una
baciloscopia positiva u´nica (incluidas las baciloscopias
paucibacilares), como casos de TB con baciloscopia
positiva. Se llevo´ a cabo un estudio retrospectivo de
cohortes en una regio´n rural de Malawi, de 1670
episodios de TB con baciloscopia positiva, 567 de los
cuales contaban con una sola baciloscopia positiva
(34%), incluidos 176 casos de una baciloscopia
paucibacilar. La tasa de mortalidad y la proporcio´n de
pacientes que iniciaron el tratamiento fue equivalente en
las personas con dos baciloscopias positivas y con una
baciloscopia no paucibacilar. Los episodios con una sola
baciloscopia paucibacilar presentaron una mortalidad
ma´s alta y una proporcio´n ma´s baja de iniciacio´n del
tratamiento. La nueva clasificacio´n aumentara´ de
manera considerable la carga de morbilidad notificada
y deberı´a mejorar el acceso al tratamiento.
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